Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.53 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | INSR | P06213 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362152 | 0.93 | EGFR (0.51) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL6357717 | 0.93 | EGFR (0.44) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL6357301 | 0.91 | EGFR (0.54) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL6358195 | 0.91 | EGFR (0.64) | EGFRERBB2ERBB4MEN1MAPK1 | |
| SCHEMBL4006437 | 0.91 | EGFR (0.50) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL6360479 | 0.90 | EGFR (0.53) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL6358431 | 0.90 | EGFR (0.59) | EGFRERBB2ERBB4GAKMEN1 | |
| SCHEMBL6362286 | 0.89 | EGFR (0.57) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL6359068 | 0.88 | EGFR (0.51) | EGFRERBB2ERBB4JAK3GAK | |
| SCHEMBL6355635 | 0.87 | EGFR (0.55) | EGFRERBB2ERBB4JAK3GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143401-A1 | Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine | COCKERILL GEORGE S (GB) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143401-A1 | Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine | ABL1, ERBB2, ERBB4 | EGFR 71/4885ERBB2 2/4885ERBB4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.